The present disclosure relates to the technical field of organic photoelectric materials, in particular to an organic compound, an electronic component containing the organic compound, and an electronic device. The compound has a structure as shown by chemical formula 1′, wherein one of R.sub.1 to R.sub.4 is aa, and the other three are selected from substituents such as an alkyl, halogen and cyano; one of R.sub.5 to R.sub.8 is bb, and the other three are selected from substituents such as an alkyl, halogen and cyano; Y and Y.sub.1 are each independently cc; and L and L.sub.1 are a single bond, aryl, heteroaryl, etc. By using the organic compound of the present disclosure in an organic component, the driving voltage, luminous efficiency and lifespan of the organic component can be improved. ##STR00001##

The present disclosure relates to the technical field of organic photoelectric materials, in particular to an organic compound, an electronic component containing the organic compound, and an electronic device. The compound has a structure as shown by chemical formula 1′, wherein one of R.sub.1 to R.sub.4 is aa, and the other three are selected from substituents such as an alkyl, halogen and cyano; one of R.sub.5 to R.sub.8 is bb, and the other three are selected from substituents such as an alkyl, halogen and cyano; Y and Y.sub.1 are each independently cc; and L and L.sub.1 are a single bond, aryl, heteroaryl, etc. By using the organic compound of the present disclosure in an organic component, the driving voltage, luminous efficiency and lifespan of the organic component can be improved. ##STR00001##

The present disclosure includes novel substituted cyclopropyl-2,2′-bipyrimidinyl compounds, and compositions comprising the same. In certain embodiments, the compounds of the disclosure can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infection in a patient.

The present invention relates to a new compound that can inhibit an anoctamin 6 protein, a composition comprising the compound, a method for preparing the compound, and a method for using the compound or composition.

The present invention relates to a new compound that can inhibit an anoctamin 6 protein, a composition comprising the compound, a method for preparing the compound, and a method for using the compound or composition.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):

##STR00001##

and/or a salt thereof, wherein R.sub.1 is —OH or —OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):

##STR00001##

and/or a salt thereof, wherein R.sub.1 is —OH or —OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

##STR00001##